Risks of Dementia Associated With Anticholinergic Medication Compared to Beta‐3 Agonist Among Older Patients With Overactive Bladder in Japan: The LIFE Study

Documenti analoghi

• Metabolic dysfunction‐associated fatty liver disease and risks of incident coronary artery disease and cerebrovascular disease: LIFE Study
  di: Yurina Akeno, et al.
  Pubblicazione: (2025)
• Incidence and temporal trends of depression and anxiety following cancer diagnosis in Japan: Insights from the LIFE study
  di: Kengo Kawaguchi, et al.
  Pubblicazione: (2025)
• Use and Persistence of Beta 3‐Adrenoceptor Agonists for the Treatment of Overactive Bladder
  di: Naoki Wada, et al.
  Pubblicazione: (2025)
• Data-Adaptive Integration With Summary Data
  di: Morikawa, Kosuke, et al.
  Pubblicazione: (2025)
• Initial real‐world experience with lecanemab prescribing patterns in Japan: The Longevity Improvement & Fair Evidence (LIFE) Study
  di: Kengo Kawaguchi, et al.
  Pubblicazione: (2026)